Loading…
Cytek Biosciences, Inc. is projected to rise to $5.18 by 2027, a +12% move from its current price of $4.62. CTKB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.50 | $4.62 | $4.75 | +0.03% |
| Jul 13 | $4.45 | $4.62 | $4.81 | +0.06% |
| Jul 14 | $4.41 | $4.62 | $4.85 | +0.10% |
| Jul 15 | $4.38 | $4.63 | $4.89 | +0.13% |
| Jul 16 | $4.35 | $4.63 | $4.92 | +0.16% |
| Jul 17 | $4.33 | $4.63 | $4.95 | +0.19% |
| Jul 18 | $4.30 | $4.63 | $4.98 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.30 | $4.63 | $4.98 | +0.23% |
| Week 2 | $4.18 | $4.64 | $5.15 | +0.45% |
| Week 3 | $4.10 | $4.65 | $5.28 | +0.68% |
| Week 4 | $4.03 | $4.66 | $5.40 | +0.91% |
| Week 5 | $3.97 | $4.67 | $5.50 | +1.14% |
| Week 6 | $3.91 | $4.68 | $5.60 | +1.37% |
| Week 7 | $3.87 | $4.69 | $5.70 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytek Biosciences, Inc. is a healthcare company that provides cell analysis tools used in biomedical research and clinical applications. The company offers systems such as Cytek aurora, northern lights systems, and Cytek aurora evo, along with the Cytek Aurora CS System, to enable cellular phenotyping and related downstream studies.
It also delivers enhanced small particle detection, Amnis imagestream imaging flow cytometers, Guava cell analyzers, and other related instruments, reagents, and software. Cytek provides cFluor reagents and automated loaders, SpectroFlo software, and customer support tools to support its product lines.
Founded in 1992 and headquartered in Fremont, California, Cytek serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes products through direct sales in North America, Europe, China, and the Asia-Pacific regions, and through distributors or sales agents in Europe, Latin America, and the Middle East. The company was formerly known as Cytoville, Inc.
and changed its name to Cytek Biosciences, Inc. in August 2015.
Cytek Biosciences, Inc. (CTKB) is listed with a current price of $4.47 and a market cap of $577.27M. It holds a relatively niche position within Healthcare, providing a range of cell analysis instruments and reagents used in biomedical research and clinical workflows. The stock is ranked 2937 by market cap among publicly traded companies.
The price outlook shows a rising path in the forward years, with the average price projected to move from $4.47 in 2026 to substantially higher levels by 2050. The forecast highlights progressively higher average prices each year, with a 2026 average of $4.47 and a 2050 average of $36.27, and notable bumps to $8.26 in 2030 and beyond. Returns improve over time, with estimated ROIs advancing from 0% in 2026 to 711.4% by 2050, and sentiment shifting to bullish through the forecast horizon.
A major floor 27.4% below — a decisive break under it would weaken the trend.
The nearest floor, 18.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.3% above — clearing it would confirm fresh momentum.
Key CTKB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTKB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.56 | Buy | $4.56 | Buy |
| MA 10 | $4.52 | Buy | $4.49 | Buy |
| MA 20 | $4.28 | Buy | $4.37 | Buy |
| MA 50 | $4.20 | Buy | $4.29 | Buy |
| MA 100 | $4.32 | Buy | $4.35 | Buy |
| MA 200 | $4.51 | Buy | $4.41 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.22 | Neutral |
| Stoch RSI (14) | 85.90 | Sell |
| CCI (20) | 87.69 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 13.51 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 0.35 | Buy |
| Ultimate (7,14,28) | 66.96 | Neutral |
| Momentum (10) | 0.15 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 4.54 | Buy |
| ADX (14) | 15.48 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is bullish overall, with RSI(14) at 60 and the price trading near key moving averages. The 50-day simple moving average is $4.21, while the 200-day simple moving average sits at $4.48, placing the current price very close to that longer-term indicator.
Support is indicated at $3.36 and resistance at $4.47. The stock has traded within a 30-day range of $3.62 to $5.53, reflecting a near-term trading band that leaves room for upside moves toward the resistance level in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.36 | $4.62 | $5.97 | 0% | Neutral | |
| $4.12 | $5.18 | $6.89 | +12% | Neutral | |
| $4.99 | $6.45 | $8.91 | +40% | Bullish | |
| $5.98 | $7.92 | $11.26 | +71% | Bullish | |
| $6.12 | $8.27 | $12.06 | +79% | Bullish | |
| $6.40 | $8.82 | $13.14 | +91% | Bullish | |
| $6.57 | $9.22 | $14.01 | +100% | Bullish | |
| $6.72 | $9.58 | $14.81 | +107% | Bullish | |
| $7.82 | $11.33 | $17.79 | +145% | Bullish | |
| $8.74 | $12.85 | $20.49 | +178% | Bullish | |
| $11.21 | $17.64 | $29.94 | +282% | Bullish | |
| $20.90 | $37.01 | $68.76 | +701% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.36 | $4.62 | $5.67 | +0.00% |
| August 2026 | $4.02 | $4.75 | $5.76 | +2.74% |
| September 2026 | $4.00 | $4.76 | $5.84 | +0.25% |
| October 2026 | $4.12 | $4.93 | $6.10 | +3.54% |
| November 2026 | $4.10 | $4.94 | $6.16 | +0.17% |
| December 2026 | $3.93 | $4.75 | $5.97 | -3.80% |
Click any year to see its month-by-month CTKB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cytek Biosciences, Inc.'s 2026 outlook centres on $4.62, within a $3.36 to $5.97 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTKB could reach as high as $6.89, with a base case around $5.18 and support toward $4.12 — roughly +12% from $4.62. Price action looks broadly range-bound.
Expect CTKB to range from $4.99 to $8.91 through 2028. The $6.45 average target implies a +40% move from current prices. That is up +25% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CTKB price prediction for 2029 points to an average of $7.92 (low $5.98, high $11.26) — a potential gain of +71% on today's $4.62. Momentum favours further upside here.
In 2030, CTKB is projected to trade between $6.12 and $12.06, averaging $8.27 — a potential gain of +79% from today's $4.62. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cytek Biosciences, Inc.'s 2031 outlook centres on $8.82, within a $6.40 to $13.14 range. That is up +7% on the projected 2030 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2032, CTKB could reach as high as $14.01, with a base case around $9.22 and support toward $6.57 — roughly +100% from $4.62. Buyers look set to stay in control over this stretch.
Expect CTKB to range from $6.72 to $14.81 through 2033. The $9.58 average target implies a +107% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The CTKB price prediction for 2034 points to an average of $11.33 (low $7.82, high $17.79) — a potential gain of +145% on today's $4.62. Buyers look set to stay in control over this stretch.
In 2035, CTKB is projected to trade between $8.74 and $20.49, averaging $12.85 — a potential gain of +178% from today's $4.62. That is up +13% on the projected 2034 average. Momentum favours further upside here.
Cytek Biosciences, Inc.'s 2040 outlook centres on $17.64, within a $11.21 to $29.94 range. That is up +37% on the projected 2035 average. That marks a +282% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTKB could reach as high as $68.76, with a base case around $37.01 and support toward $20.90 — roughly +701% from $4.62. Momentum favours further upside here.
Investing $1,000 in CTKB today (≈ 216.450216 CTKB) could be worth
$8,011.8
+$7,011.8 (+701%) by 2050 · US Dollar
Based on the average projected CTKB price of $37.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTKBwould be worth at today's price.
$1,000 invested in CTKB on Jul 10, 2025 (≈ 280.898881 CTKB) would be worth
$1,297.75
+$297.75 (+29.8%) today · 1.30× · US Dollar
Based on a CTKB entry price of $3.56 vs. today's $4.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.59 | $1,006.54 | +0.7% |
| 1 month ago | $4.05 | $1,140.74 | +14.1% |
| 3 months ago | $4.53 | $1,019.87 | +2.0% |
| 6 months ago | $5.8 | $796.55 | -20.3% |
| 1 year ago | $3.56 | $1,297.75 | +29.8% |
| All time (5.0y) ago | $18.76 | $246.27 | -75.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTKB forecast.
Our base-case forecast reaches $9.20 around 2032.
Implied market cap at $9.20: $1.19B
The multi-year forecast shows a clear uptrend in average prices and sizable upside, with 2026 averaging $4.47 (ROI 0%) and 2027 averaging $5.12 (ROI 14.6%). By 2028 the average is projected at $6.30 (ROI 40.9%), and by 2029 at $7.86 (ROI 75.8%), with 2030 averaging $8.26 (ROI 84.8%). The path continues higher through 2031 at $8.49 (ROI 90%), 2032 at $9.04 (ROI 102.1%), and 2033 at $9.41 (ROI 110.6%).
By 2034 the average price is forecast at $10.89 (ROI 143.6%), and 2035 at $12.79 (ROI 186.1%). The forecast grows more dramatically later, with 2040 averaging $17.16 (ROI 283.8%) and remaining bullish, and 2050 averaging $36.27 (ROI 711.4%). The 2050 forecast also shows a max of $71.50 and a min of $18.68, underscoring a broad range of potential outcomes.
These projections reflect a bullish long-term outlook but carry inherent uncertainty and are not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast gives an average price of $8.26 with a minimum of $5.93 and a maximum of $12.46, and an expected ROI of 84.8% with a bullish sentiment.
The forecast shows a positive, bullish trajectory in the longer term, with increasing average prices and rising ROIs: 2027 avg $5.12 (ROI 14.6%), 2028 avg $6.30 (ROI 40.9%), 2029 avg $7.86 (ROI 75.8%), 2030 avg $8.26 (ROI 84.8%), and continuing higher through 2050 (avg $36.27, ROI 711.4%). In 2026 the sentiment is neutral with an average of $4.47 and ROI of 0%.
The 2040 forecast max is $30.61, and the 2050 forecast max is $71.50, indicating possible upside to reach or exceed $30 by 2040 and much higher by 2050.
The current price is $4.47. The 30-day range is from a low of $3.62 to a high of $5.53.
The 2050 forecast shows an average price of $36.27 with a min of $18.68 and a max of $71.50, and a projected ROI of 711.4% with a bullish sentiment.
Cytek Biosciences, Inc. Community Discussion
0Share your Cytek Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.